Menu
Close
Global
×

Company News

Company News
Company News
2026-01-05
ImmuneOnco R&D Vice President Mr. Li Song Selected for Shanghai's 2025 "Oriental Talent Program"
Recently, the list of selected candidates for the 2025 Shanghai "Oriental Talent Program" (Top Tier) was officially announced. Mr. Li Song, Vice President of Research and Development at ImmuneOnco Bio
View more
2025-12-15
ImmuneOnco Successfully Holds Interim Investigator Meeting in Beijing for Phase Ib/II Clinical Study of Amulirafusp Alfa (IMM0306) Injection in Active Systemic Lupus Erythematosus
ImmuneOnco successfully convened the interim investigator meeting for the "Phase Ib/II Clinical Study of Amulirafusp Alfa (IMM0306) Injection in Active Systemic Lupus Erythematosus (SLE)" in Beijing.
View more
2025-12-09
2025 ASH | ImmuneOnco Announces Positive Progress from Phase I/II Study of IMM0306 Combined with Lenalidomide for Relapsed/Refractory CD20-Positive Follicular Lymphoma
December 9, 2025 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco", Hong Kong Stock Exchange code: 01541.HK) today announced that the company presented data from
View more
2025-11-27
ImmuneOnco's Amulirafusp Alfa (IMM0306) Phase III Clinical Trial Protocol Approved by CDE, Accelerating Development of Novel Therapy for Relapsed/Refractory Follicular Lymphoma
Amulirafusp Alfa (IMM0306), in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma (FL), has been formally approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)
View more
2025-10-31
Positive Progress of Amulirafusp Alfa (IMM0306) in the Treatment of Systemic Lupus Erythematosus (SLE) Presented at ACR Convergence 2025
On October 28, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco," with the stock code 01541.HK on the Hong Kong Stock Exchange) presented the latest results of the Phase
View more
2025-10-02
Application for Phase III Clinical Trial of IMM2510 for IO-Resistant Non-Small Cell Lung Cancer Submitted to CDE
Application for Phase III Clinical Trial of IMM2510 for IO-Resistant Non-Small Cell Lung Cancer Submitted to CDE
View more
总计 92 12345678...1516